文档下载 文档下载导航
设为首页 | 加入收藏
搜索 请输入内容:  
 导航当前位置: 文档下载 > 所有分类 > 医药卫生 > 肿瘤微环境双重响应性的智能型蛋白毒素给药系统的构建和表征
侵权投诉

肿瘤微环境双重响应性的智能型蛋白毒素给药系统的构建和表征

2.6 TCS-Asn10-Hz-PEG

Ё Ё ▔ Ё Ё Ё [12] Ё г ∈ ┃ ┃ legubicin legubicin Ё ┃ ┃ ┑ [13] TCS C TCS-Asn6-Hz- PEG TCS TCS-Asn10-Hz-PEGЁ 24 h 30% TCS 8 1 TCS

肿瘤微环境双重响应性的智能型蛋白毒素给药系统的构建和表征

[6] [5] [4] [3]

PEG TCS PEG TCS TCS PEG ∈ pH TCS

REFERENCES

[1] [2]

[7]

[8]

[9]

8 TCS-Asn10-Hz-PEG

Fig. 8 The proteolysis of TCS-Asn10-Hz-PEG 1 TCS-Asn10-Hz-PEG ё

Tab. 1 Legumain proteolysis of TCS-Asn10-Hz-PEG

TCS-b-PEG/%

TCS/%

/%

0 h 94 6

2 h 77.7 22.3

4 h 73.3 26.7

6 h 74.8 25.2

12 h 73.1 26.9

24 h 69.3 30.7

48 h 69.1 30.9

[10]

[11]

[12]

[13]

3

EVALUATE PHARMA. Biotech set to dominate drug industry growth [R]. 2009.

LI M, CHEN F, LIU C P, et al. Dexamethasone enhances trichosanthin-induced apoptosis in the HepG2 hepatoma cell line [J]. Life Sci, 2010, 86(1/2): 10-16.

ZHANG K, XU J, HUANG X, et al. Trichosanthin down-regulated p210Bcr-Abl and enhanced imatinib-induced growth arrest in chronic myelogenous leukemia cell line K562 [J]. Cancer Chemother Pharmacol, 2007, 60(4): 581-587.

LEE K M, WONG K B, SHAW P C. Recent advances in trichosanthin, a ribosome inactivating protein with multiple pharmacological properties. Toxicon, 2005, 45(6): 683-689JIANG X Z. Manufactural method for a warm external medicament: China, 88105607.3 [P]. 2010-07-26.

AN Q, LEI Y, JIA N, et al. Effect of site-directed PEGylation of trichosanthin on its biological activity, immunogenicity, and pharmacokinetics [J]. Biomol Eng, 2007, 24(6): 643–649.

CHAN W L, SHAW P C, LI X B, et al. Lowering of trichosanthin immunogenicity by site-specific coupling to dextran [J]. Biochem Pharmacol, 1999, 57(8): 927-934.

FEE C J, VAN ALSTINE J M. PEG-proteins: Reaction engineering and separation issues [J]. Chem Eng Sci, 2006, 61(3): 924-939.

PASUT G, VERONESE F M. PEGylation for improving the effectiveness of therapeutic biomolecules [J]. Drugs Today (Barc), 2009, 45(9): 687-695.

NARIMATSU S, YOSHIOKA Y, WATANABLE H, et al. Lysine-deficient lymphotoxin-α mutant for site-specific PEGylation [J]. Cytokine, 2011, 56(2): 489-493.

LEE E S, GAO Z, BAE Y H. Recent progress in tumor pH targeting nanotechnology [J]. J Control Release, 2008, 132(2): 164-170.

WU W, LUO Y, SUN C, et al. Targeting cell-impermeable prodrug activation to tumor microenvironment eradicates multiple drug-resistant neoplasms [J]. Cancer Res, 2006, 66(2): 970-980.

EROGLU A, SARI A. Expression of c-kit proto-oncogene product in breast cancer tissues [J]. Med Oncol, 2007, 24(2): 169-174.

LIU C, SUN C Z, HUANG H N, et al. Overexpression of Legumain in tumors is significant for invasion/metastasis and a candidate enzymatic target for prodrug therapy [J]. Cancer Res, 2003, 63(11): 2957-2964.

2014-01-02

Ё 2014 11 31 11 Chin J Mod Appl Pharm, 2014 November, Vol.31 No.11 g1301g

上一页第5页

你可能喜欢

热门文档

相关文档

站点地图 | 文档上传 | 侵权投诉 | 手机版
本站所有资源均来自互联网,本站只负责收集和整理,均不承担任何法律责任,如有侵权等其它行为请联系我们.
文档下载 Copyright 2013 doc.guandang.net All Rights Reserved.  -  email